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Abstract 
The impact of left ventricular hypertrophy
(LVH) on survival among patients with estab-
lished coronary artery disease (CAD) is not
well  understood.  We  sought  to  evaluate  the
effect of LVH on the survival of patients with
CAD  following  percutaneous  coronary  inter-
vention (PCI). Three hospitals in New York
City contributed prospectively defined data on
4284 consecutive patients undergoing PCI. All-
cause mortality at a mean follow-up of three
years was the primary endpoint. LVH was pres-
ent in 383 patients (8.9%). LVH patients had a
greater prevalence of hypertension (88% vs.
68%,  p<0.001),  vascular  disease  (21%  vs.
6.6%, p=0.001), and prior heart failure (10%
vs.  5.5%,  p<0.001).  LVH  patients  presented
less  often  with  one-vessel  disease  (38%  vs.
50%, p=0.040) and more often with two- (34%
vs.  29%,  p=0.014)  or  three-vessel  (22%  vs.
18%, p=0.044) disease. Ejection fractions and
angiographic  success  were  similar  in  both
groups.  In-hospital  mortality  did  not  differ
between groups. At three-year follow-up, the
survival rate for patients with LVH was 86% vs.
91%  in  patients  without  LVH  (log-rank
p=0.001). However, after adjustment for dif-
ferences in baseline characteristics using Cox
proportional hazards analysis, LVH was found
not to be an independent predictor of mortali-
ty (hazard ratio, 0.93; 95% confidence interval,
0.68-1.28; p=0.67). We conclude that LVH at
the time of PCI is not independently associat-
ed with an increase in the hazard of death at
three years. 
Introduction
It is well documented that left ventricular
hypertrophy (LVH) detected by 12-lead electro-
cardiography or echocardiography is a signifi-
cant risk factor for cardiovascular morbidity
and mortality in cohorts ranging from the gen-
eral population to those with established car-
diovascular disease, including coronary artery
disease (CAD).
1-10 However, the impact of LVH
on survival among patients with established
CAD  following  revascularization  is  largely
unknown. The current study was designed to
evaluate the effect of LVH on long-term out-
comes of patients with CAD following revascu-
larization with percutaneous coronary inter-
vention (PCI).
Patients and Methods
Patient population
The study population was a cohort of 4284
consecutive  patients  undergoing  PCI  from
January 1, 1998 to October 1, 1999 at three
hospitals in New York City. 
Clinical data
Prospectively defined data elements were
contributed to a central coordinating center
for analysis. Data elements included informa-
tion on demographics, comorbidities, proce-
dural details, complications, and in-hospital
outcomes.  The  same  data  elements  are
required to be submitted to the Department
of  Health  on  every  PCI  performed  in  New
York  State  to  make  up  the  Coronary
Angioplasty Reporting System database. 
Definitions
LVH was defined by physician assessment
of the pre-PCI ECG or by echocardiography in
documented cases of left bundle branch block
and/or pacing. Diabetes included treatment
with  oral  hypoglycemic  agents  or  insulin.
Intravenous  glycoprotein  (GP)  IIb/IIIa
inhibitors  were  administered  when  abcix-
imab,  eptifibatide,  or  tirofiban  were  given
during or within three hours following PCI.
The diagnosis of peri-procedural myocardial
infarction (MI) required new Q-waves and a
rise in creatine kinase to at least 2.5 times
the upper limit of normal occurring within 24
hours of the PCI. Heparin therapy indicated
treatment  with  intravenous  heparin  within
48 hours before the PCI. Nitroglycerin treat-
ment  indicated  therapy  with  intravenous
nitroglycerin within 24 hours of the proce-
dure for ongoing ischemia or left ventricular
failure. Ventricular arrhythmias were those
that occurred within seven days of the PCI
requiring  electrical  are  pharmacological
treatment excluding episodes that occurred
within  the  first  24  hours  of  an  MI.  Angio-
graphic success was a reduction of the treat-
ed  lesion  by  at  least  20%  with  a  residual
stenosis of less than 50%. 
Percutaneous coronary intervention 
All procedural decisions, including device
selection  and  adjunctive  pharmacotherapy,
were made at the discretion of the individual
physician  performing  PCI.  All  stents  were
bare metal. Deployment was at high pressure
and  patients  were  maintained  on  aspirin
indefinitely, and ticlopidine or clopidrogel for
four weeks following their PCI unless con-
traindicated. Angiographic assessments were
made  at  the  individual  hospital  by  visual
assessment. 
Endpoints
The primary endpoint was all-cause mor-
tality following discharge from the hospital
for  the  index  PCI  as  determined  from  the
Social Security Death Index. This index has
been shown to be highly specific and unbi-
ased.
11,12 Follow-up was for a mean of three
years.
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Statistical analysis
Categorical variables were compared by ˇ
2-
analyses. Continuous variables are presented
as mean ± SD and were compared using the
Student’s t-test. All probability values are two-
tailed. Statistical significance was defined as
p<0.05  or  confidence  intervals  that  did  not
include 1.0. Survival curves were constructed
by the Kaplan-Meier method with differences
in  survival  assessed  with  the  log-rank  test.
LVH was related to all-cause mortality using
multivariable Cox proportional hazard regres-
sion analyses to adjust for differences in base-
line  characteristics.  Potential  confounders
were entered into models if they were clinical-
ly relevant or showed univariable differences
between  groups  with  a  p<0.10.  All  analyses
were performed using the SPSS (Chicago, IL,
USA) statistical analysis program.
Results 
Baseline characteristics
LVH  was  identified  in  383  (8.9%)  of  4284
patients who underwent PCI for CAD. Baseline
characteristics  of  patients  are  presented  in
Table 1. Patients with LVH were older (66 vs. 63
years, p=0.001) and less often characterized as
white  (66%  vs.  79%,  p<0.001).  LVH  patients
had a lower prevalence of smoking (9.4% vs.
14%, p=0.019) but greater prevalence of hyper-
tension (88% vs. 68%, p<0.001), diabetes (31%
vs. 26%, p=0.041), vascular disease (21% vs.
6.6%,  p<0.001),  creatinine  of  >2.5  mg/dL,
(3.7%  vs.  1.7%,  p=0.009),  dialysis  (3.9%  vs.
1.5%, p<0.001), and prior heart failure (10% vs.
5.5%, p<0.001). 
Procedural characteristics
Angiographic and procedural characteristics
are depicted in Table 2. LVH patients presented
less  often  with  one-vessel  disease  (38%  vs.
50%, p=0.04) and more often with two-vessel
(34% vs. 29%, p=0.01) and three-vessel disease
(22% vs. 18%, p=0.04). Mean ejection fraction
was  lower  in  LVH  patients  (49%  vs.  51%,
p=0.01).  Stent  placement  did  not  differ  in
either group. Angiographic success was similar
in both groups (98% vs. 97%, p=0.27).
Outcomes
Adverse outcomes following PCI are depicted
in Table 3. In-hospital adverse outcomes includ-
ing death, post-PCI MI, and stent thrombosis
were not different between groups. There was a
greater rate of emergency bypass surgery in the
LVH group (0.5% vs. 0.1%, p=0.004). The mor-
tality at a mean follow-up of three years for
patients with LVH was 14% vs. 8.9% in patients
without  LVH  (Figure  1)  (log-rank  p<0.001).
The independent predictors of long-term mor-
tality as determined by Cox proportional haz-
ards analysis are presented in Table 4. LVH was
not independently associated with an increase
in the hazard of long-term mortality (hazard
ratio, 0.93; 95% confidence interval, 0.68-1.28;
p=0.67).  Clinical  characteristics  associated
with an increased hazard for long-term mortal-
ity were age, prior history of heart failure, vas-
cular  disease,  diabetes,  creatinine  of  >2.5
mg/dL, and dialysis.  
Discussion
The significant findings of this retrospec-
tive, observational study are two-fold. First, in
an unselected population of patients undergo-
ing PCI for CAD, LVH was associated with an
increase in unadjusted three-year mortality.
Second,  after  adjustment  for  differences  in
baseline characteristics, LVH was no longer
Table 1. Baseline characteristics.
LVH No LVH p
(N=383) (N=3901)
Demographics
Mean age ± SD (years) 66.6±11.4 63.1±11.9 <0.001
Age > 75 years (%) 27 18 <0.001
Female (%) 35 31 0.06
White (%) 66 79 <0.001
Body mass index ± SD 28.1±5.8 28.6±6.0 0.13
Clinical history (%)
Obesity 30 33 0.14
Smoking 9.4 14 0.02
Hypertension 88 68 <0.001
Diabetes 31 26 0.04
Stroke 0.3 0.1 0.51
Vascular disease  21 6.6 <0.001
Creatinine >2.5 mg/dL 3.7 1.7 0.009
Dialysis 3.9 1.5 <0.001
Cardiac history (%)
Previous CHF 10 6 <0.001
Prior MI 37 35 0.45
Previous cardiac surgery 18 17 0.74
Previous PCI 25 26 0.84
Clinical presentation (%)
CHF 12 4.3 <0.001
MI <6 hours 2.6 4 0.17
MI <24 hours 4.2 6.5 0.08
Unstable angina 45 42 0.27
Heparin <48 hours 31 29 0.46
Nitroglycerin <24 hours 16 13 0.09
Ventricular arrhythmia 2.1 1.9 0.82
Thrombolysis <6 hours  0.3 0.7 0.32
Thrombolysis >6 hours 0.8 3.4 0.005
Shock 2.6 2.5 0.88
LVH, left ventricular hypertrophy; CHF, congestive heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Table 2. Angiographic and procedural characteristics.
LVH No LVH p
(N=383) (N=3901)
Mean ejection fraction ± SD (%) 51 51 0.70
One-vessel CAD (%) 38 50 <0.001
Two-vessel CAD (%) 34 29 0.02
Three-vessel CAD (%) 22 18 0.04
IABP (%) 1.8 1.3 0.43
Stent (%) 74 77 0.13
GP IIb/IIIa inhibitor (%) 21 24 0.23
Angiographic success (%) 98 97 0.27
Atherectomy (%) 15 13 0.41
LVH, left ventricular hypertrophy; SD, standard deviation; CAD, coronary artery disease; IABP, intra-aortic balloon pump; GP, glycoprotein.Article
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associated with an increased hazard of death.
LVH  has  long  been  associated  with  an
increased  risk  of  cardiovascular  mortality.
1-8
However, there is a paucity of data regarding
its impact in patients with CAD and even less
information on the effect of LVH on prognosis
of patients with CAD following percutaneous
revascularization. East and colleagues found
echocardiographic LVH to be associated inde-
pendently  with  a  56%  increase  in  risk  of
three-year  mortality  among  patients  with
CAD.
13 However,  only  37%  of  LVH  patients
underwent  revascularization  compared  to
51%  of  patients  without  LVH  despite  more
three-vessel  disease  in  the  LVH  group.
Likewise the Heart and Soul Study found that
increased  LV  mass  index  determined  by
echocardiography  in  patients  with  CAD
increased the risk for both all-cause mortality
and  sudden  or  arrhythmic  death.
9 Again  in
this study, although all patients had CAD, only
62% with LVH had been revascularized. 
LVH may be associated with increased mor-
tality by a number of mechanisms. Activation
of  the  renin-angiotensin  system  not  only
leads to LVH but also may promote the pro-
gression of atherosclerosis by the effects of
angiotensin  II  on  vasomotor  tone,  coagula-
tion, and vascular smooth muscle cell prolifer-
ation.
14-17 Additionally, LVH may predispose to
arrhythmic death. Myocardial fibrosis occurs
in  LVH  and  may  provide  the  substrate  for
reentrant ventricular arrhythmias.
18-21
It is unclear why the current study found no
detrimental  effect  of  LVH  on  three-year
adjusted mortality. One potential explanation
is methodological. This database uses prima-
rily the ECG for diagnosis of LVH, which is
less sensitive for the detection of LVH than
echocardiography.
22,23 Thus, if the ECG were
insensitive, patients with LVH would be incor-
rectly assigned to the group without LVH. In
such a scenario, if LVH were truly an inde-
pendent  risk  factor  for  mortality,  assigning
patients with LVH to the no-LVH group would
minimize or eliminate any true differences in
mortality. Alternatively, it is possible that cer-
tain elements of the medical therapy for sec-
ondary prevention following PCI, such as ʲ-
blockers and angiotensin converting enzyme
inhibitors,
24 induced regression of LVH, which
has been shown to reduce mortality.
25 Finally,
it is possible that in the setting of CAD, the
adverse effect of LVH on survival is magnified
in the presence of untreated or unrecognized
ischemia. In this scenario, revascularization
would  eliminate  or  reduce  ischemia  and
thereby decrease the impact of LVH on mor-
tality to an undetectable level in a cohort of
this size.
Several limitations must be borne in mind
when analyzing these findings. First, because
of  its  nonrandomized  retrospective  nature,
there  may  be  unrecognized  differences
Table 4. Cox proportional hazards model for all-cause mortality.
Variable Hazard 95 % Confidence intervals p
ratio Lower Upper
LVH 0.93 0.68 1.28 0.67
Age (per one-year increase) 1.07 1.06 1.08 <0.001
Vascular disease 1.42 1.07 1.89 0.01
Diabetes 1.47 1.18 1.84 0.001
Previous CHF 2.04 1.53 2.73 <0.001
One-vessel CAD 0.58 0.40 0.83 0.003
Two-vessel CAD 0.69 0.48 0.99 0.048
Creatinine of >2.5 mg/dL 3.41 2.38 4.90 <0.001
Dialysis 4.02 2.68 6.02 <0.001
Female  0.74 0.60 0.93 0.008
LVH, left ventricular hypertrophy; CHF, congestive heart failure; CAD, coronary artery disease. 
Female  0.74 0.60 0.93 0.00
Figure 1. Kaplan-Meier analysis of survival following percutaneous coronary interven-
tion (log-rank p<0.001).
Table 3. Adverse outcomes following percutaneous coronary intervention.
LVH No LVH p
(N=383) (N=3901)
In-hospital death (%) 0.8 0.4 0.34
Emergency bypass surgery (%) 0.5 0.1 0.004
Myocardial infarction (new Q-waves) (%) 0 0.2 0.41
Myocardial infarction (no new Q-waves) (%) 1.6 1.5 0.93
Vascular complication (%) 0.1 0 0.48
Abrupt closure (%) 0.5 0.5 0.93
Stent thrombosis (%) 0.8 0.6 0.69
Out-of-hospital death (%) 14 9 0.002
LVH, left ventricular hypertrophy.
No LVH
LVH
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between patients with and without LVH in our
study. One possible confounder is medication
usage,  which  was  impossible  to  control  for
because  there  were  no  data  on  medication
use in the database. Second, there were no
uniform ECG criteria for the diagnosis of LVH.
Thus,  different  methods  of  LVH  determina-
tion probably were used by different practi-
tioners.  Finally,  this  study  was  performed
before the introduction of drug-eluting stents.
However, it is unlikely that the exclusive use
of bare metal stents would have impacted dif-
ferentially on patients with and without LVH.
Conclusion
The  current  study  demonstrates  that,
although LVH is a marker for increased mor-
tality, it does not increase independently the
hazard of mortality among patients with CAD
following PCI.  
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